Sunitinib dose-escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Sunitinib is considered a first-line therapeutic option for patients with advanced clear cell renal cell carcinoma (ccRCC). Despite sunitinib clinical efficacy, eventually patients develop drug resistance and disease progression. Herein, we tested the hypothesis whether initial sunitinib resistance...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Cancer Ther
Hauptverfasser: Adelaiye, Remi, Ciamporcero, Eric, Miles, Kiersten Marie, Sotomayor, Paula, Bard, Jonathan, Tsompana, Maria, Conroy, Dylan, Shen, Li, Ramakrishnan, Swathi, Ku, Sheng-Yu, Orillion, Ashley, Prey, Joshua, Fetterly, Gerald, Buck, Michael, Chintala, Sreenivasulu, Bjarnason, Georg A., Pili, Roberto
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326587/
https://ncbi.nlm.nih.gov/pubmed/25519701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0208
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge